Avidity Partners Management LP Has $8.24 Million Holdings in Repligen Corporation $RGEN

Avidity Partners Management LP lifted its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 115.9% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 50,300 shares of the biotechnology company’s stock after acquiring an additional 27,000 shares during the period. Repligen makes up about 2.4% of Avidity Partners Management LP’s investment portfolio, making the stock its 10th biggest position. Avidity Partners Management LP owned 0.09% of Repligen worth $8,242,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. United Capital Financial Advisors LLC bought a new position in shares of Repligen during the 3rd quarter worth about $368,387,000. Holocene Advisors LP lifted its holdings in shares of Repligen by 47.0% during the 3rd quarter. Holocene Advisors LP now owns 1,377,104 shares of the biotechnology company’s stock worth $184,077,000 after acquiring an additional 440,290 shares during the period. Massachusetts Financial Services Co. MA bought a new position in shares of Repligen during the 4th quarter worth about $199,176,000. Alliancebernstein L.P. lifted its holdings in shares of Repligen by 21.8% during the 3rd quarter. Alliancebernstein L.P. now owns 1,104,171 shares of the biotechnology company’s stock worth $147,595,000 after acquiring an additional 197,778 shares during the period. Finally, Conestoga Capital Advisors LLC lifted its holdings in shares of Repligen by 10.6% during the 4th quarter. Conestoga Capital Advisors LLC now owns 1,057,975 shares of the biotechnology company’s stock worth $173,360,000 after acquiring an additional 101,062 shares during the period. 97.64% of the stock is owned by institutional investors.

Repligen Trading Down 2.1%

RGEN opened at $130.59 on Friday. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $7.37 billion, a PE ratio of 145.10, a PEG ratio of 2.51 and a beta of 1.09. Repligen Corporation has a 1-year low of $100.99 and a 1-year high of $175.77. The firm has a 50-day moving average price of $120.23 and a two-hundred day moving average price of $137.90.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.10. The firm had revenue of $194.26 million during the quarter, compared to analysts’ expectations of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.39 EPS. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, equities analysts anticipate that Repligen Corporation will post 1.99 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Wolfe Research assumed coverage on shares of Repligen in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 target price for the company. JPMorgan Chase & Co. dropped their target price on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Weiss Ratings upgraded shares of Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, May 7th. Royal Bank Of Canada assumed coverage on shares of Repligen in a research report on Thursday, May 14th. They set an “outperform” rating and a $160.00 target price for the company. Finally, Barclays increased their target price on shares of Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $164.64.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.